Stock screener

NTLA

Conviction 24HealthcareScan · Mon, Aug 10, 2026
NTLA$12.02+0.67%
ResistanceSupportVol 14
63 bars
Vol MA14 3.78M
May 11May 28Jun 16Jul 6Jul 23Aug 10
Intellia Therapeutics, Inc.IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESwww.intelliatx.com
Price12.02
Change+0.67%
Gap-0.59%
Rel volume1.10×
Avg volume3.95M
Avg $ vol45.18M
SMA 2011.37
SMA 5013.51
SMA 20012.65
Price vs 50-11.00%
Price vs 200-4.98%
MA stackmixed
50/200 cross
Supertrenddown · 12.83
RSI (14)48
MACD hist0.21
MACD crossbull · 3d
Stoch %K / %D89 / 85
ADX (14)32
+DI / −DI21 / 26
RSI divergence
MACD divergence
ATR %+6.36%
ADR %5.15%
52w high27.98
52w low8.04
From 52w high-57.04%
Above 52w low+49.50%
New 52w highNo
SqueezeOff
Bollinger width25.37%
%B0.73
Donchian pos54.68%
Donchian high13.57
Donchian low10.15
AVWAP (52w high)13.02
vs AVWAP high-7.69%
AVWAP (52w low)12.90
vs AVWAP low-6.80%
OBV trendFlat
Chaikin MF (20)-0.05
Today vs 20d1.10×
Avg vol (14d)3.78M
Avg vol (20d)3.95M
Avg $ vol (20d)45.18M
Market cap1.68B
RS 3m (vs SPY)-18.61%
RS 6m (vs SPY)-6.45%
RS line new highNo
Trend template3/8
Technical rank26.9
1 week+11.61%
1 month-15.44%
3 months-14.69%
6 months-2.12%
1 year+4.89%
YTD+30.51%
P/E-4.08
P/B2.31
P/S24.89
P/FCF-4.25
EPS-3.81
Div yield
ROE-56.71%
ROA-48.15%
Debt/Eq
Current6.65
EV/EBITDA-3.66
Gross margin
Net margin-609.85%
Rev growth16.92%
EPS growth20.49%
Price target19.15
Target upside59.32%
Analyst ratingBuy
Institutional95.03%
Ent. value1.58B
Revenue7.66M
Net income-106.63M
Gross profit
Free cash flow-395.87M
IndustryIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
ExchangeNasdaq
Shares out139.72M
Employees377
ListedFri, May 6, 2016
Free float96.07M
Float %82.9%
Short interest45.78M
Days to cover9.8d
Short volume55.7%
Squeeze score77 / 100
Next earnings
EPS forecast
Last EPS vs est−$0.80 vs −$0.80
Last surprise0.0% beat
Setup gradeD
Conviction24 / 100
Pattern quality
Tech rank26.9 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction
Pattern family
Resistance17.61
Support10.28
Days since event
Candle confirm
News sentiment

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in NTLA

All disclosures →
No recent disclosed trades by Congress in NTLA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in NTLA · 10 buys

InsiderSideShares
Cohen Fred E
Director · Common Stock · 2026-06-09
Grant9.2K
Verwiel Frank
Director · Common Stock · 2026-06-09
Grant9.2K
Bhanji Muna
Director · Stock Option (right to buy) · 2026-06-09
Grant13.3K
Keresty Georgia
Director · Common Stock · 2026-06-09
Grant9.2K
Keresty Georgia
Director · Stock Option (right to buy) · 2026-06-09
Grant13.3K
GOODMAN JESSE
Director · Common Stock · 2026-06-09
Grant9.2K
GOODMAN JESSE
Director · Stock Option (right to buy) · 2026-06-09
Grant13.3K
CHASE WILLIAM J
Director · Common Stock · 2026-06-09
Grant9.2K
Verwiel Frank
Director · Stock Option (right to buy) · 2026-06-09
Grant13.3K
Goff Brian
Director · Common Stock · 2026-06-09
Grant9.2K

SEC filings

EDGAR filings in NTLA · 6 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.